iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/15207960/
Live flavivirus vaccines: reasons for caution - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Jun 19;363(9426):2073-5.
doi: 10.1016/S0140-6736(04)16459-3.

Live flavivirus vaccines: reasons for caution

Stephen J Seligman  1 , Ernest A Gould
Affiliations
Review

Live flavivirus vaccines: reasons for caution

Stephen J Seligman et al. Lancet. .

Abstract

Context: Dengue, Japanese encephalitis, tick-borne encephalitis, yellow fever, and West Nile viruses cause substantial morbidity and mortality each year. Modern transportation and the relaxation of mosquito-control measures are largely responsible for the increase of disease caused by flaviviruses. Without effective antiviral drugs, vaccination offers the best chance of decreasing the incidence of these diseases, and live virus vaccines are the most promising and cost effective. However, flaviviruses can recombine, which raises the possibility of recombination between a vaccine strain and wild-type virus resulting in a new virus with potentially undesirable properties.

Starting point: Recently, Arunee Sabchareon and colleagues reported up to 90% seroconversion rates in a phase I trial of live-attenuated dengue-virus vaccines in children (Pediatr Infect Dis J 2004; 23: 99-109). Other live flavivirus vaccines have also been tested against dengue, Japanese encephalitis, and West Nile viruses. Thus far, efficacy seems promising.

Where next: Safety issues with the live flavivirus vaccines need to be recognised and addressed. The theoretical possibility of untoward recombination events can never be entirely dismissed, but steps can be taken to minimise risk. The development of non-live flavivirus vaccines should be encouraged.

PubMed Disclaimer

Comment in

  • Arguments for live flavivirus vaccines.
    Hombach J, Kurane I, Wood D. Hombach J, et al. Lancet. 2004 Aug 7-13;364(9433):498-9. doi: 10.1016/S0140-6736(04)16800-1. Lancet. 2004. PMID: 15302184 No abstract available.
  • Arguments for live flavivirus vaccines.
    Murphy BR, Blaney JE Jr, Whitehead SS. Murphy BR, et al. Lancet. 2004 Aug 7-13;364(9433):499-500. doi: 10.1016/S0140-6736(04)16801-3. Lancet. 2004. PMID: 15302187 No abstract available.
  • Arguments for live flavivirus vaccines.
    de Silva A, Messer W. de Silva A, et al. Lancet. 2004 Aug 7-13;364(9433):500. doi: 10.1016/S0140-6736(04)16802-5. Lancet. 2004. PMID: 15302188 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources